Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


28.05.2018

1 Int J Neurosci
1 J Neurol
7 Lancet Neurol
1 Mult Scler
1 PLoS One
1 Rev Neurol
5 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Int J Neurosci

  1. MARKOVA J, Essner U, Akmaz B, Marinelli M, et al
    Sativex(R) as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.
    Int J Neurosci. 2018 May 24:1-26. doi: 10.1080/00207454.2018.1481066.
    PubMed     Text format     Abstract available


    J Neurol

  2. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Text format     Abstract available


    Lancet Neurol

  3. ROMMER PS, Zettl UK
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2018;17:497-498.
    PubMed     Text format    

  4. PETZOLD A
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2018;17:496-497.
    PubMed     Text format    

  5. SCHWENKENBECHER P, Wurster U, Suhs KW, Stangel M, et al
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2018;17:498.
    PubMed     Text format    

  6. SECHI E, Keegan BM, Flanagan EP
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2018;17:498-499.
    PubMed     Text format    

  7. THOMPSON AJ, Reingold SC, Cohen JA
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply.
    Lancet Neurol. 2018;17:499-500.
    PubMed     Text format    

  8. CHATAWAY J
    Tackling progression in multiple sclerosis.
    Lancet Neurol. 2018;17:489-491.
    PubMed     Text format    

  9. ETEMADIFAR M, Sabeti F
    Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.
    Lancet Neurol. 2018;17:497.
    PubMed     Text format    


    Mult Scler

  10. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Text format     Abstract available


    PLoS One

  11. MARCK CH, De Livera AM, Brown CR, Neate SL, et al
    Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up.
    PLoS One. 2018;13:e0197759.
    PubMed     Text format     Abstract available


    Rev Neurol

  12. EICHAU S, Lopez-Ruiz R, Ruiz-Pena JL, Paramo MD, et al
    [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Rev Neurol. 2018;66:395-396.
    PubMed     Text format    


    Rev Neurol (Paris)

  13. MAAROUF A, Boutiere C, Rico A, Audoin B, et al
    How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update.
    Rev Neurol (Paris). 2018 May 17. pii: S0035-3787(17)30864.
    PubMed     Text format     Abstract available

  14. MAILLART E
    Treatment of progressive multiple sclerosis: Challenges and promising perspectives.
    Rev Neurol (Paris). 2018 May 17. pii: S0035-3787(17)30828.
    PubMed     Text format     Abstract available

  15. LOUAPRE C
    Conventional and advanced MRI in multiple sclerosis.
    Rev Neurol (Paris). 2018 May 18. pii: S0035-3787(17)30849.
    PubMed     Text format     Abstract available

  16. THOUVENOT E
    Multiple sclerosis biomarkers: Helping the diagnosis?
    Rev Neurol (Paris). 2018 May 18. pii: S0035-3787(18)30563.
    PubMed     Text format     Abstract available

  17. RUET A
    Update on pediatric-onset multiple sclerosis.
    Rev Neurol (Paris). 2018 May 18. pii: S0035-3787(17)30852.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: